web discussion boards |
||||
|
News for 19-May-26 Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General |
The Best web discussion boards websiteAll the web discussion boards information you need to know about is right
here. Presented and researched by http://www.mdnewscast.net. We've searched
the information super highway far and wide to provide you with the
best web discussion boards site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
web discussion boards
The Web has evolved into a global electronic publishing medium and increasingly, a medium for conducting electronic commerce in areas such as web discussion boards. Electronic commerce means that you can purchase web discussion boards products online. One of the major downsides of the Internet is that ignorant people may pose as quasi-experts. If someone states they are a web discussion boards authority then that statement is certainly open to dispute. Organizations who specialize in the production and marketing of web discussion boards are more likely to know what they are doing then a quasi web discussion boards expert. We have devoted a lot of time and resources to locating the most reliable web discussion boards suppliers from a large list of web discussion boards websites. If you click on the links and banners of this page then you'll enter the most appropriate area for web discussion boards purchases. web discussion boards
web discussion boards - a high stand of informationWhen you’re seeking information about web discussion boards the results can seem extremely overwhelming. But relax, because we’ve sifted through all the web discussion boards web sites we could find and have discovered the finest ones that will produce the results you want, and how you want them. We know how crucial good results are when you’re searching for web discussion boards. Some Internet sites are superior than others and will meet your web discussion boards requirements in a better fashion. If you’re looking for a high standard web discussion boards site you know you can count on, we suggest the above web site. We have taken the tiresome task out of your web discussion boards shopping and reduced our list of web discussion boards web sites down to only finest around. Being assured you’re receiving value for money is crucial in buying web discussion boards, so by visiting our web site you can expect the assurance that you are getting the web discussion boards you paid for. By purchasing through our suggested links you can also rest assured your web discussion boards will be of a high standard. How do we know? Because when we’re shopping for web discussion boards ourselves it’s where we go. You might be pondering why we’re suggesting you visit outside links rather than stay on our own web discussion boards site. Well it’s because we’ve only recently created our site so it's early days. Our goal is to be the best site for web discussion boards info on the net, and real soon we’ll achieve it. So please bookmark us and come back soon. Class of Drugs Brings Hope to Cancer Patients by: ARA Content
(ARA) - This is an exciting time in cancer research. Recent information on angiogenesis -- the growth of new blood vessels -- is providing researchers opportunities to find new ways to slow or stop a tumor's growth by cutting off the blood supply it needs. Angiogenesis performs a critical role in the development of cancer. To grow, solid tumors need oxygen and nutrients provided by new blood vessels. Once a vascular network has been generated, cancer cells can also invade the rest of the body, a process called metastasis. Currently, researchers believe that more than 90 percent of all cancer cases are angiogenesis-dependent. The good news is that a novel class of drugs, which acts as angiogenesis inhibitors, shows great potential in fighting more than 20 different diseases, including many types of cancer. These "anti-angiogenesis" drugs being developed and tested block the formation of new blood vessels, starving cancerous cells and stopping tumor growth. One drug being tested, Neovastat, was discovered in 1994 and is derived from cartilage tissue. Neovastat is the only angiogenesis inhibitor being developed in the biotechnology and pharmaceutical universe that has four mechanisms of action to combat blood vessel growth. Furthermore, Neovastat is taken orally, making it convenient for patients who need long-term treatment, and it has shown minimal side effects in clinical trials. This means that unlike standard chemotherapy, Neovastat is not likely to interfere with a patient's immune system, or cause adverse gastrointestinal symptoms or hair loss. In addition, because most cancer cells are genetically unstable and more prone to mutations, resistance is a major problem with many chemotherapy agents. But since anti-angiogenesis drugs target normal endothelial cells that are not genetically unstable, drug resistance is less likely to develop and has not been a problem so far in clinical trials. Another hope is that angiogenesis inhibitors can be used in combination with therapies that directly target tumor cells. Because anti-angiogenic drugs and chemotherapy are aimed at different cellular targets, it is possible that the combination will prove even more effective than either therapy is as a stand-alone. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer for which there are urgent needs for new therapies. For multiple myeloma, the second most common form of blood cancer, the drug is in phase two trials with 125 patients in the United States, Canada and Europe. This trial should be completed by the end of 2002. For progressive renal cell carcinoma, the drug is in phase three trials with 280 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a phase three trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005. Once the clinical trials are complete, health authorities in various countries can then assess test results and make decisions on approval. Neovastat is being developed by Aeterna Laboratories of Quebec, Canada. For more information about current trials, call (888) 349-3232. If you are an oncologist, contact Claude Hariton, PhD, vice president of Clinical and Regulatory Affairs, (418) 652-8525, Ext. 306. To learn more about anti-angiogenesis and Aeterna Laboratories, visit the Aeterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.
|
|||
|
http://www.medmeet.com/ |
||||
| Medical Newscast Medical On the Net Internet Meetings |